Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeant's Board of DirectorsMay 16, 2013 7:56 am | News | Comments
Valeant Pharmaceuticals International, Inc. announced that Dr. Laurence Paul has resigned from Valeant's Board of Directors due to expanded business, philanthropic, and personal commitments. Dr. Paul was originally elected to Biovail Corporation's Board of Directors in June 2002 where he served in several capacities.
Actavis Inc. said Wednesday it acquired a bacterial vaginosis gel developed by Valeant Pharmaceuticals International Inc. Actavis said it agreed to pay Valeant $55 million for its metronidazole gel product, which has not yet received marketing approval. The total includes both an upfront payment...
Actavis and Valeant Pharmaceuticals today announced that Actavis has reached settlement agreements with Medicis Pharmaceutical Corporation, a subsidiary of Valeant, resolving outstanding patent litigation related to Actavis' Abbreviated New Drug Application for Clindamycin and Tretinoin Gel, a generic version of Ziana, as well as Actavis' ANDA for Imiquimod Cream, a generic version of Zyclara.
German drugmaker Merz Pharma Group has ended a plan to acquire Obagi Medical Products Inc. after a competitor raised its bid to buy the dermatology products maker. Merz said Monday it is a "disciplined buyer," and it was withdrawing its $22-per-share cash bid for Obagi after Canadian drugmaker Valeant Pharmaceuticals raised its offer last week to $24 per share.
Valeant Pharmaceuticals International Inc. said Thursday that a newly approved generic version of one of its drugs could significantly reduce its profits this year. Mylan Inc. on Wednesday received final approval from the U.S. Food and Drug Administration to sell the first generic version of...
Valeant Pharmaceuticals International, Inc. today announced that Valeant and Obagi Medical Products, Inc. have executed an amendment to their Agreement and Plan of Merger, dated March 19, 2013. Pursuant to the amendment, Valeant increased its offer to acquire Obagi from $19.75 to $24.00 per share in cash.
German drugmaker Merz Pharma Group said Tuesday that it wants to buy dermatology products maker Obagi for about $383.5 million, toping an offer made by Canada's Valeant Pharmaceuticals last month. Merz said it sent a letter to Obagi Medical Products Inc.'s board offering to buy all of the company's stock for $22 per share.
Valeant Pharmaceuticals International Inc. reported a fourth-quarter loss, as acquisition-related costs countered steep revenue growth for the Canadian drugmaker. Valeant focuses on dermatology, neurology and branded generics. Its products include the antidepressant Wellbutrin XL and the blood...
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Valeant Pharmaceuticals International, Inc. announced today that Valeant has acquired U.S. rights for Targretin (bexarotene) capsules and Targretin (bexarotene) gel 1% from Eisai for $65 million upfront, plus potential contingent payments based on certain milestones
Valeant Pharmaceuticals International, Inc. has reached agreement on terms of a revised North American aesthetics arrangement with Galderma S.A.
Valeant Pharmaceuticals International, Inc. announced today that Ryan Weldon and Jason Hanson will be named to Valeant's Executive Management Team.
Valeant Pharmaceuticals has announced that Rajiv De Silva, Valeant's President and Chief Operating Officer of Specialty Pharmaceuticals, will be leaving the company to pursue other interests.
Valeant Pharmaceuticals International, Inc. announced today that Valeant has agreed to acquire OraPharma, a specialty oral health company that develops and commercializes products that improve and maintain oral health, from Water Street Healthcare Partners.
MONTREAL — Valeant Pharmaceuticals International Inc. expects to grow in emerging and niche markets that aren't being eyed by "big pharma," chief executive officer Michael Pearson said Wednesday.
Valeant Pharmaceuticals International, Inc. announced today that it has agreed to acquire certain assets from Swiss Herbal Remedies Limited, a nutraceutical company that manufactures and markets a broad range of scientifically formulated vitamins, minerals and supplements, for less than one times sales.
Valeant Pharmaceuticals International, Inc. announced today that Valeant has signed an agreement to acquire certain assets from Atlantis Pharma, a branded generics pharmaceutical company located in Mexico with a broad product portfolio, including products in the gastro, analgesics and anti-inflammatory therapeutic categories, for approximately $71 million.
Valeant Pharmaceuticals International, Inc. announced today that the company has acquired Pedinol Pharmacal, Inc., a podiatry-focused, privately-owned specialty pharmaceutical company based in the U.S., for less than 1.5 times sales.
Valeant Pharmaceuticals International Inc. said Tuesday that it is buying a generic aspirin and other products from Austrian generic drugmaker Gerot Lannach as part of a push to expand in Eastern Europe.
Valeant Pharmaceuticals International, Inc. announced today that the company has acquired a 19.9% minority equity investment in Pele Nova Biotecnologia S.A. a Brazilian research company focused on tissue regeneration.
Valeant Pharmaceuticals has agreed to acquire Eyetech Inc., a privately-owned ophthalmic biotechnology company dedicated to the treatment of sight-threatening diseases of the retina, for an upfront payment and potential future milestones that total significantly less than two times sales.
Valeant Pharmaceuticals International, Inc. today announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to Mylan Inc.
Valeant Pharmaceuticals International, Inc. today announced that it has withdrawn its offer to acquire ISTA Pharmaceuticals Inc. for $7.50 per share in cash.
ISTA Pharmaceuticals announced today that it has received a revised non-binding proposal from Valeant Pharmaceuticals to acquire ISTA and will consider the updated proposal as part of its ongoing review of strategic options.
TORONTO — Valeant Pharmaceuticals expects to find $200M of cost savings this year as it works to fully incorporate drug companies acquired in a nearly $3-billion buying spree since merging with Biovail.